MedPath

Shanghai Cell Therapy Research Institute

🇨🇳China
Ownership
Private
Established
2014-08-27
Employees
-
Market Cap
-
Website
http://www.shcell.org/

PD-1 Antibody Expressing mesoCAR-T Cells for Mesothelin Positive Advanced Solid Tumor

Phase 1
Conditions
Advanced Solid Tumor
Interventions
Biological: PD-1 antibody expressing mesoCAR-T cells
First Posted Date
2018-08-03
Last Posted Date
2018-08-03
Lead Sponsor
Shanghai Cell Therapy Research Institute
Target Recruit Count
50
Registration Number
NCT03615313
Locations
🇨🇳

China, Shanghai, Shanghai, China

CTLA-4 and PD-1 Antibodies Expressing EGFR-CAR-T Cells for EGFR Positive Advanced Solid Tumor

Phase 1
Conditions
Advanced Solid Tumor
Interventions
Biological: anti-CTLA-4/PD-1 expressing EGFR-CAR-T
First Posted Date
2017-06-09
Last Posted Date
2017-06-09
Lead Sponsor
Shanghai Cell Therapy Research Institute
Target Recruit Count
40
Registration Number
NCT03182816
Locations
🇨🇳

Ningbo No.5 Hospital (Ningbo Cancer Hospital), Ningbo, Zhejiang, China

CTLA-4 and PD-1 Antibodies Expressing Mesothelin-CAR-T Cells for Mesothelin Positive Advanced Solid Tumor

Phase 1
Conditions
Advanced Solid Tumor
Interventions
Biological: CTLA-4/PD-1 antibodies expressing mesoCAR-T
First Posted Date
2017-06-09
Last Posted Date
2017-06-09
Lead Sponsor
Shanghai Cell Therapy Research Institute
Target Recruit Count
40
Registration Number
NCT03182803
Locations
🇨🇳

Ningbo No.5 Hospital (Ningbo Cancer Hospital), Ningbo, Zhejiang, China

CTLA-4 and PD-1 Antibodies Expressing MUC1-CAR-T Cells for MUC1 Positive Advanced Solid Tumor

Phase 1
Conditions
Advanced Solid Tumor
Interventions
Biological: Anti-CTLA-4/PD-1 expressing MUC1-CAR-T
First Posted Date
2017-06-07
Last Posted Date
2017-06-07
Lead Sponsor
Shanghai Cell Therapy Research Institute
Target Recruit Count
40
Registration Number
NCT03179007
Locations
🇨🇳

Ningbo No.5 Hospital (Ningbo Cancer Hospital), Ningbo, Zhejiang, China

© Copyright 2025. All Rights Reserved by MedPath